後発医薬品（シンバスタチン製剤）の治療学的同等性に関してのレトロスペクティブな使用実態調査成績
スポンサーリンク
概要
- 論文の詳細を見る
We conducted a retrospective study to determine whether a brand-name simvastatin (Lipovas®) is therapeutically equivalent to a generic simvastatin (Lipodown®). One hundred and sixty-nine subjects were chosen from among hyperlipidemia patients who had been visiting Keihanna Hospital and Matsumoto Medical Clinic. These patients had been switched from the brand name simvastatin, Lipovas® to the generic product Lipodown® in the course of their treatment for hyperlipidemia. Clinical data for 36 of the 169 subjects were analyzed.Regarding efficacy, no significant differences were seen in total cholesterol levels before switching to Lipodown® and six months after switching (217.6±36.7 mg/dL→212.4±26.1 mg/dL (at time of switch)→209.9±27.7 mg/dL, P=0.11), and this was also the case for HDL-cholesterol, LDL-cholesterol, and triglyceride levels. We also analyzed drug safety using AST, ALT, γ-GTP, BUN, Creatinine and CPK as indices and found no specific problems related to the switch to Lipodown®. These results suggest that Lipovas® and Lipodown® are therapeutically equivalent, and that Lipodown® can be used clinically in place of Lipovas® so long as essential markers like ALT, AST, γ-GTP, and CPK are carefully monitored.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)